Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavorixafor (Primary)
  • Indications WHIM syndrome
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Sponsors X4 Pharmaceuticals

    • Most Recent Events

    • 19 Oct 2019 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
    • 19 Oct 2019 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.
    • 26 Jun 2019 Status changed from not yet recruiting to recruiting as per an X4 Pharmaceuticals, Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top